MAP - Market Access Podcast

By Dr. Stefan Walzer

Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.


Category: Business

Open in Apple Podcasts


Open RSS feed


Open Website


Rate for this podcast
    

Subscribers: 0
Reviews: 0
Episodes: 86

Description

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries. The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves. Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany). Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition. Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.

Episode Date
Are We Overlooking the Real Benefits of Medical Innovation, Dr. Ahmed Seddik?
Apr 15, 2025
What Are the Biggest Challenges in Implementing AI in Pharma, Jan Kroschinski?
Apr 01, 2025
How Can Startups Leverage Market Access to Attract Investors, Johan Olsson?
Mar 15, 2025
How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali?
Mar 01, 2025
How Can Innovation Planning Transform Market Access Success, Dr. Kasia Hein-Peters?
Feb 15, 2025
How does early Market Access bridge the gap between innovation and commercial success, Catherine Bacon?
Feb 01, 2025
A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala? (Repost)
Jan 15, 2025
What happens, when negotiations fail, Prof. Dr. Jürgen Wasem? (Repost)
Dec 15, 2024
How can people get equal access to pharmaceuticals, Dr. Nina Lathia? (Repost)
Dec 01, 2024
How might digitization change health care in Germany by 2035, Julian Molitor? (Repost)
Nov 15, 2024
How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters? (Repost)
Nov 01, 2024
What does environmental sustainability mean for Market Access, Gerdi Strydom?
Oct 15, 2024
What are the main obstacles in oncology market access, Ed Schoonveld? (Repost)
Oct 01, 2024
Is there a place for Real World Evidence in HTA, Dr. Karen Facey? (Repost)
Sep 15, 2024
How should market access and medical affairs work together, Dr. Mike Rosenblatt? (Repost)
Sep 01, 2024
Summer Special - Webinar: How AI can revolutionize dossier writing, with special guest Aleksey Zavgorodniy
Aug 15, 2024
What are the latest trends in Turkish Healthcare Market Access, Oznur Seyhun?
Aug 01, 2024
How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes?
Jul 15, 2024
How can Virtual Reality become a game-changer in Healthcare Training, Rodrigo Silva?
Jul 01, 2024
How Can AI Unlock the Potential of Market Access, Sandip Shah?
Jun 15, 2024
What Does the Future Hold for AI in Healthcare, Aleksey Zavgorodniy?
Jun 01, 2024
How to Decode Market Access in Canada: Are There Essential Tips for Success, Tara Cowling and Jody Filkowski?
May 15, 2024
How has virtual become reality in market access, Glib Kutepov?
May 01, 2024
What Makes Italy's Healthcare System So Complex, Giacomo Matteo Bruno?
Apr 16, 2024
Is Healthcare Just a Business in the US, Aymeric Chaupin?
Apr 01, 2024
A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala?
Mar 15, 2024
Mastering US Market Access: What are proven Strategies for Success, Paul-Lukas Hoffschmidt?
Mar 01, 2024
Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?
Feb 15, 2024
Remo Christen – Early paid access in Switzerland – Switzerland, wonderland? (Repost)
Feb 01, 2024
How can we overcome the complexity of market access for medical devices in Spain, Sergio Gil?
Jan 15, 2024
What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian? (Repost)
Dec 15, 2023
The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff
Dec 01, 2023
Navigating the Healthcare Startup Galaxy - key insights with Dr. Thomas Kerscher and Mark Anken.
Nov 15, 2023
How to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?
Nov 01, 2023
AMNOG 2.0 - significant changes for the industry since January 2023, correct - Dr. Flume?
Oct 15, 2023
Inside the Swiss decision-makers - how does the system for drugs really work, Dr. Heiner Sandmeier?
Oct 01, 2023
How should market access and medical affairs work together, Dr. Mike Rosenblatt?
Sep 15, 2023
📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra?
Sep 01, 2023
How does an optimized communication strategy look like, Dr. Arne Näveke?
Aug 15, 2023
How does the German evaluation committee work, Prof. Jürgen Wasem?
Aug 01, 2023
How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters?
Jul 15, 2023
How do I get approved by the US FDA, Dr. Jamie Cross?
Jul 01, 2023
How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?
Jun 15, 2023
How does market access work in Japan, Heather Wellam?
Jun 01, 2023
Would AI substitute or (only) support market access managers, Dr. Andree Bates? (Repost)
May 15, 2023
Is there a place for Real World Evidence in HTA, Dr. Karen Facey?
May 01, 2023
How can people get equal access to pharmaceuticals, Dr. Nina Lathia?
Apr 15, 2023
How to be successful in Canadian health care market access & pricing!
Apr 01, 2023
How can companies prepare for EU Joint HTA, Priyanka Kiritharan and Chloe Sheppard?
Mar 15, 2023
Is quality cancer care in Ukraine still possible, Yevgen Brovko?
Mar 01, 2023
What are drivers for a positive approval by Health Canada, Fraidianie Sévignè?
Feb 15, 2023
EU joint HTA – decided, but how will it be executed and how should companies prepare, Dr. Elvira Müller?
Feb 01, 2023
The US pricing reform has an impact on Europe as well, correct Dr. Renato Dellamano and Jack Mycka?!
Jan 15, 2023
What are the main obstacles in oncology market access, Ed Schoonveld?
Jan 01, 2023
Why should companies get early advice from payers, Esther Nzenza and Dr. Nick Leach?
Dec 15, 2022
The AMNOG process - how does it work from a legal perspective, Alexander Meier?
Dec 01, 2022
What are the hot topics in market access based on ISPOR Europe 2022, Dr. Stefan Walzer?
Nov 15, 2022
AMNOG Reform - will Germany remain the most attractive market for orphan drugs?
Nov 01, 2022
Why should Market Access Managers care about statistics, Alexander Schacht?
Oct 15, 2022
How might digitization change health care in Germany by 2035, Julian Molitor?
Oct 01, 2022
Are selective contracts with German insurances a smarter reimbursement pathway, Tim Hering?
Sep 15, 2022
Would AI substitute or (only) support market access managers, Dr. Andree Bates?
Sep 01, 2022
How successful is the DiGA fast track, Dr. Henrik Matthies ?
Aug 15, 2022
The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?
Aug 01, 2022
Switzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?
Jul 15, 2022
AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?
Jul 01, 2022
What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian?
Jun 15, 2022
Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graaff?
Jun 01, 2022
The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?
May 15, 2022
Is European market access really so difficult? Tell us the truth being successful in Europe, Esther Nzenza!
May 01, 2022
What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?
Apr 15, 2022
Digital Health Care is already fully utilized in the US, isn’t it?
Apr 01, 2022
Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?
Mar 15, 2022
What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?
Mar 01, 2022
The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?
Feb 15, 2022
How can a company derive the optimal price for their medical product, Dr. Renato Dellamano?
Feb 01, 2022
How do innovations reach patients in German hospitals, Dr. Sebastian Casu?
Jan 15, 2022
How does hospital funding work in Germany, Willi Wöllner?
Jan 01, 2022
Prof. Dr. Jürgen Wasem - What happens, when negotiations fail?
Dec 15, 2021
Dr. Michael Zuercher - Commercial attractiveness of the Swiss health care market – success starts with market access.
Dec 01, 2021
Prof. Peter Zweifel & Door Vonk - Digital innovation - from theory into practice!
Nov 15, 2021
Bibiane Schulte-Bosse - How to fight well in AMNOG negotiations.
Nov 01, 2021
Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?
Oct 15, 2021
Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??
Oct 01, 2021
Prof. Dr. Wagschal - What can we expect from the upcoming elections in Germany?
Sep 15, 2021
Dr. Mathias Flume - AMNOG will change in 2022, but how?
Sep 02, 2021